IP Library Granted Patent US 8,444,856
Granted Patent B2
US 8,444,856 · App. 13/569,733 · Granted May 21, 2013

Chromatography of metal complexes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,444,856
App. No.
13/569,733
Granted
May 21, 2013
Kind
B2
Abstract

A high performance liquid chromatography method to routinely and reproducibly detect and quantitate metal complexes is provided. The metal complexes used in the method of the invention can be different metal complexes, or they can be stereoisomers of the same metal complexes. The high performance liquid chromatography method of the present invention is suitable for the separation of diastereomers of the same metal complexes. Also provided is a chiral high performance liquid chromatography method to separate enantiomers of metal complexes. Superoxide dismutase mimetic compounds are also provided.

Claims (24)

1. A high performance liquid chromatography method comprising:

loading a solution containing a mixture of metal complexes comprising one or more of a Mn II (1,4,7,10,13-pentaazacyclopentadecane) complex having the structure

its diastereomers, its enantiomer, and imine oxidation products, onto a column,

eluting the metal complexes from the column with a mobile phase, said mobile phase comprising an excess of a salt of a coordinating anion in a solvent system, and

detecting the eluted metal complexes with a detector, wherein X is the coordinating anion.

2. The method of claim 1 wherein the metal complexes comprise products of a reaction stream.

3. The method of claim 1 wherein the mixture of metal complexes comprises the Mn II (1,4,7,10,13-pentaazacyclopentadecane)complex and its diastereomers.

4. The method of claim 1 wherein the mixture of metal complexes comprises the Mn II (1,4,7,10,13-pentaazacyclopentadecane)complex and its enantiomer, the enantiomer having the structure

wherein X is the coordinating anion.

5. The method of claim 1 wherein the coordinating anions comprise chloride anions, thiocyanate anions, stearate anions, acetate anions, trifluoroacetate anions, carboxylate anions, formate anions or azide anions.

6. The method of claim 1 wherein the salt comprises sodium chloride, lithium chloride, potassium chloride, ammonium chloride, tetrabutylammonium chloride, sodium thiocyanate, potassium thiocyanate, ammonium thiocyanate, lithium thiocyanate, potassium acetate, sodium acetate, ammonium acetate, ammonium trifluoroacetate, lithium acetate, potassium formate, sodium formate, ammonium formate, lithium formate, sodium cyanate, potassium cyanate, ammonium cyanate, potassium carboxylate, sodium carboxylate, lithium stearate, sodium stearate, sodium azide, potassium azide or lithium azide.

7. The method of claim 1 wherein the salt comprises sodium chloride, lithium chloride or tetrabutylammonium chloride.

8. The method of claim 7 wherein the sodium chloride is present in the mobile phase at a concentration of between about 0.1 M to about 1 M.

9. The method of claim 1 wherein the salt comprises ammonium thiocyanate, sodium thiocyanate or potassium thiocyanate.

10. The method of claim 1 wherein the solvent system comprises a solvent.

11. The method of claim 10 wherein the solvent comprises acetonitrile, dioxane, ethanol, methanol, isopropanol, tetrahydrofuran, or water.

12. The method of claim 1 wherein the solvent system comprises a mixture of solvents.

13. The method of claim 12 wherein the mixture of solvents comprises two or more of acetonitrile, dioxane, ethanol, methanol, isopropanol, tetrahydrofuran, and water.

14. The method of claim 13 wherein the solvents comprise acetonitrile and water.

15. The method of claim 13 wherein the solvents comprise methanol and water.

16. The method of claim 1 wherein the salt is present in the mobile phase at a concentration of between about 0.004 M to about 6 M.

17. The method of claim 1 wherein the column is selected from the group consisting of a C1 modified column, a C3 modified column, a C4 modified column, an octyl (C8) modified column, an octadecyl (C18) modified column, a C18 polymer column, a phenyl column, and an amino-cyano column.

18. The method of claim 1 wherein the column comprises a chiral column.

19. The method of claim 1 wherein the detector comprises a UV detector.

Assignments (8)
BILL OF SALE Recorded Aug 29, 2018
From: ACTIVBIOTICS, INC.; METAPHORE PHARMACEUTICALS, INC.
To: KEREOS, INC.; INOTEK PHARMACEUTICALS CORPORATION
Reel/Frame 046974/0889 →
LICENSE Recorded Aug 29, 2018
From: INOTEK PHARMACEUTICALS CORPORATION
To: GALERA THERAPEUTICS, LLC
Reel/Frame 047317/0760 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2018
From: INOTEK PHARMACEUTICALS CORPORATION
To: GALERA THERAPEUTICS, LLC
Reel/Frame 046742/0485 →
CHANGE OF NAME Recorded Aug 26, 2015
From: GALERA THERAPEUTICS, LLC
To: GALERA LABS, LLC
Reel/Frame 036427/0622 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2015
From: ACTIVBIOTICS, INC.; METAPHORE PHARAMCEUTICALS, INC.
To: KEREOS, INC.; INOTEK PHARMACEUTICALS CORPORATION
Reel/Frame 035276/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2015
From: INOTEK PHARMACEUTICAL CORPORATION
To: GALERA THERAPEUTICS, LLC
Reel/Frame 035276/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2015
From: KEREOS, INC.
To: GALERA THERAPEUTICS, LLC
Reel/Frame 035276/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2015
From: SLOMCZYNSKA, URSZULA J.; TRAWICK, BOBBY N.; RILEY, DENNIS P.; NAIK, ARATI
To: METAPHORE PHARMACEUTICALS, INC.
Reel/Frame 035276/0246 →